Life Sciences

Why licensing deals are a powerful source of growth in life sciences

Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.

How implementation unlocks the true potential of AI in pharma

Discover why robust AI implementation is crucial for pharma innovation and how overcoming challenges leads to success.

Life sciences dealmaking in a time of change

Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.

Supply chain visibility strategic priority for pharma

With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.

How digital is changing the tax strategy for MedTech

As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.

Innovation can utilize data for value-based care

Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.

Life sciences businesses transform tax and finance

Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.

Why life sciences tax departments need to act now on sustainability

Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.

How innovative infostructure can power the purpose of integrated care systems

Sharing organized and complete data to generate insights for better health outcomes is the driving force behind joined-up care in integrated care systems (ICSs).

How the challenge of regulating AI in healthcare is escalating

Artificial intelligence is forcing healthcare regulators to play catch-up and reimagine the regulation rule book.

How do you build future supply chains to best serve patient needs?

In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.

CDMOs are becoming emerging technology leaders

Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.

How to navigate global transfer pricing controversy in life sciences

Life sciences companies face growing tax authority scrutiny of their transfer pricing practices and must prepare for escalating controversy.

How you can create value in an intelligent health ecosystem

The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.

How to navigate EU regulations for drug-device combination products

The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.

Are digital twins key to more personal, equitable and efficient care?

Digital patient twins tap into the transformative value data beyond the traditional medical to provide health providers and payers actionable insights. Learn more at ey.com/smarthealth.